Assess whether management can run this without the founder (2a0721)

Situation

A health-system acquiring a specialty practice cannot treat an earnout based on 'adjusted EBITDA' with no dictionary as color commentary on regulatory-approval critical-path calendar. Buy-side QoE lead must close management can run this from that extract under M&A Due Diligence / Legal, IP, and Regulatory.

Decision

Buy-side QoE lead in a health-system acquiring a specialty practice must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary.

Hypotheses to test

• Regulatory-approval critical-path calendar reads as Proceed once an earnout based on 'adjusted EBITDA' with no dictionary is lined up to the same M&A Due Diligence population.
• Regulatory-approval critical-path calendar is closer to Reprice after an earnout based on 'adjusted EBITDA' with no dictionary; Proceed would over-claim this Legal, IP, and Regulatory extract.
• Walk is still live in regulatory-approval critical-path calendar for buy-side QoE lead in a health-system acquiring a specialty practice.
• Regulatory-approval critical-path calendar is missing the fact buy-side QoE lead needs after an earnout based on 'adjusted EBITDA' with no dictionary; stop this M&A Due Diligence close.

Analysis required

• Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar.
• Map reps, earnout mechanics, and integration risk a health-system acquiring a specialty practice would inherit.
• Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to management can run this.
• For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against an earnout based on 'adjusted EBITDA' with no dictionary and write the one fact that would move management can run this for buy-side QoE lead.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary). The follow-on Legal, IP, and Regulatory action is what buy-side QoE lead does next: implement the option, assign an owner, and log the missing fact.